由β-arrestins介导的β-上腺素受体信号传递及其在心力衰竭中的潜在作用
Preston C Nibley1,2, Sudha K Shenoy1,2
1Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Current opinion in physiology
|December 14, 2023
概括
了解心力衰竭 (HF) 中的β-停止蛋白信号传递对于治疗心血管疾病 (CVD) 至关重要. β-arrestins调节β-上腺素受体 (β-AR) 路径,提供潜在的心脏保护策略.
科学领域:
- 心血管生物学 心血管生物学
- 分子药理学分子药理学
- 细胞信号传输 细胞信号传输
背景情况:
- 心力衰竭 (HF) 致死率,特别是SARS-CoV-2感染后 (PASC) 相关的心肌炎,突出了了解心血管疾病 (CVD) 细胞通路的必要性.
- 甲基胺结合β-上腺素受体 (β-ARs) 是心血管调节中的关键G蛋白结合受体 (GPCRs).
- 在β-AR信号传递中,β-阿雷斯具有双重作用:灭G蛋白通路并启动独立级联.
研究的目的:
- 阐明β-ARs复杂的信号机制,重点关注β-arrestins在心血管生理学和病理学中的多方面的作用.
- 探索β-arrestin相互作用和翻译后修改如何影响β-AR信号传输.
- 为了研究β-arrestin偏差激素和全调节的潜在心脏保护作用.
主要方法:
- 关于β-AR和β-arrestin信号通路的现有文献的审查和综合.
- 分析GPCR信号动态,包括正规G蛋白通路和β-阿雷斯介导事件.
- 检查翻译后修改和全调节剂对受体活性的影响.
主要成果:
- β-arrestins是β-AR信号的关键调节者,能够抑制G蛋白级联并启动不同的信号通路.
- 翻译后的修改显著影响β-arrestin功能和下游信号结果.
- 像卡维迪醇这样的β-arrestin偏差配体和基调节剂通过选择性向β-AR信号来证明心脏保护的潜力.
结论:
- 由于GPCR信号的复杂性,我们需要更深入地了解β-arrestin在心血管健康和疾病中的作用.
- 通过β-arrestin偏差和全性机制对β-AR信号的向调节为心血管疾病提供了有前途的治疗途径.
- 对新药和内源性修饰的进一步研究是有必要的,以充分利用这些途径的心脏保护潜力.
相关概念视频
Adrenergic Receptors: β Subtype
1.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.7K
Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
828
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
828
Antihypertensive Drugs: Action of β1 Blockers
450
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
450
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Adrenergic Receptors (Adrenoceptors): Classification
2.6K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.6K


